;PMID: 9377572
;source_file_2888.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..188] = [t:46..188]
;2)section:[e:192..282] = [t:192..282]
;3)section:[e:286..388] = [t:286..388]
;4)sentence:[e:392..586] = [t:392..586]
;5)sentence:[e:587..781] = [t:587..781]
;6)sentence:[e:782..967] = [t:782..967]
;7)sentence:[e:968..1216] = [t:968..1216]
;8)sentence:[e:1217..1372] = [t:1217..1372]
;9)section:[e:1376..1420] = [t:1376..1420]

;section 0 Span:0..40
;Cancer Res.  1997 Oct 15;57(20):4578-84.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[13..17] 1997)
        (NNP:[18..21] Oct) (CD:[22..24] 15) (CD:[24..27] ;57)
        (-LRB-:[27..28] -LRB-) (CD:[28..30] 20) (-RRB-:[30..31] -RRB-)
        (CD:[31..36] :4578) (CD:[36..39] -84) (.:[39..40] .)))

;sentence 1 Span:46..188
;High levels of expression and nuclear localization of interleukin-1 beta 
;converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.
;[100..137]:gene-protein:"interleukin-1 beta  converting enzyme"
;[139..142]:gene-protein:"ICE"
;[148..153]:gene-protein:"CPP32"
;[173..187]:malignancy-type:"neuroblastomas"
(SENT
  (NP-HLN
    (NP (JJ:[46..50] High) (NNS:[51..57] levels))
    (PP (IN:[58..60] of)
      (NP
        (NP
          (NP (NN:[61..71] expression))
          (CC:[72..75] and)
          (NP (JJ:[76..83] nuclear) (NN:[84..96] localization)))
        (PP (IN:[97..99] of)
          (NP
            (NP
              (NP
                (ADJP
                  (NML (NN:[100..113] interleukin-1) (SYM:[114..118] beta))
                  (VBG:[120..130] converting))
                (NN:[131..137] enzyme))
              (NP (-LRB-:[138..139] -LRB-) (NN:[139..142] ICE)
                  (-RRB-:[142..143] -RRB-)))
            (CC:[144..147] and)
            (NP (NN:[148..153] CPP32))))))
    (PP-LOC (IN:[154..156] in)
      (NP (JJ:[157..166] favorable) (JJ:[167..172] human)
          (NNS:[173..187] neuroblastomas)))
    (.:[187..188] .)))

;section 2 Span:192..282
;Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su MS, Zhao H, Cnaan A,
; Sakiyama S.
(SEC
  (FRAG (NNP:[192..202] Nakagawara) (NNP:[203..204] A) (,:[204..205] ,)
        (NNP:[206..214] Nakamura) (NNP:[215..216] Y) (,:[216..217] ,)
        (NNP:[218..223] Ikeda) (NNP:[224..226] H,) (NNP:[227..233] Hiwasa)
        (NNP:[234..235] T) (,:[235..236] ,) (NNP:[237..242] Kuida)
        (NNP:[243..245] K,) (NNP:[246..248] Su) (NNP:[249..251] MS)
        (,:[251..252] ,) (NNP:[253..257] Zhao) (NNP:[258..260] H,)
        (NNP:[261..266] Cnaan) (NNP:[267..268] A) (,:[268..269] ,)
        (NNP:[271..279] Sakiyama) (NNP:[280..282] S.)))

;section 3 Span:286..388
;Division of Biochemistry, Chiba Cancer Center Research Institute, Japan. 
;akiranak@biolab.kazusa.or.jp
(SEC
  (FRAG (NNP:[286..294] Division) (IN:[295..297] of)
        (NNP:[298..310] Biochemistry) (,:[310..311] ,) (NNP:[312..317] Chiba)
        (NNP:[318..324] Cancer) (NNP:[325..331] Center)
        (NNP:[332..340] Research) (NNP:[341..350] Institute) (,:[350..351] ,)
        (NNP:[352..357] Japan) (.:[357..358] .)
        (``:[360..385] akiranak@biolab.kazusa.or) (NN:[385..388] .jp)))

;sentence 4 Span:392..586
;Neuroblastomas frequently show spontaneous regression and differentiation,
;which  may at least partly be regulated by signaling through nerve growth
;factor and  its receptors, TRK-A and p75LNTR.
;[392..406]:malignancy-type:"Neuroblastomas"
;[528..547]:gene-protein:"nerve growth factor"
;[568..573]:gene-protein:"TRK-A"
;[578..585]:gene-protein:"p75LNTR"
(SENT
  (S
    (NP-SBJ (NNS:[392..406] Neuroblastomas))
    (ADVP (RB:[407..417] frequently))
    (VP (VBP:[418..422] show)
      (NP (JJ:[423..434] spontaneous) (NN:[435..445] regression)
          (CC:[446..449] and) (NN:[450..465] differentiation))
      (,:[465..466] ,)
      (SBAR-ADV
        (WHNP-1 (WDT:[467..472] which))
        (S
          (NP-SBJ-1 (-NONE-:[472..472] *T*))
          (VP (MD:[474..477] may)
            (ADVP
              (PP (IN:[478..480] at)
                (ADJP (JJS:[481..486] least)))
              (RB:[487..493] partly))
            (VP (VB:[494..496] be)
              (VP (VBN:[497..506] regulated)
                (NP-1 (-NONE-:[506..506] *))
                (PP (IN:[507..509] by)
                  (S-NOM-LGS
                    (NP-SBJ (-NONE-:[509..509] *))
                    (VP (VBG:[510..519] signaling)
                      (PP (IN:[520..527] through)
                        (NP
                          (NP (NN:[528..533] nerve) (NN:[534..540] growth)
                              (NN:[541..547] factor))
                          (CC:[548..551] and)
                          (NP
                            (NP (PRP$:[553..556] its) (NNS:[557..566] receptors))
                            (,:[566..567] ,)
                            (NP (NN:[568..573] TRK-A) (CC:[574..577] and)
                                (NN:[578..585] p75LNTR))))))))))))))
    (.:[585..586] .)))

;sentence 5 Span:587..781
;We studied 52 neuroblastic tumors to test  whether the cell death-related
;proteases, interleukin-1 beta converting enzyme  (ICE), CPP32, and Ich-1,
;were involved in the regression of the tumors.
;[601..620]:malignancy-type:"neuroblastic tumors"
;[661..670]:gene-protein:"proteases"
;[672..708]:gene-protein:"interleukin-1 beta converting enzyme"
;[711..714]:gene-protein:"ICE"
;[717..722]:gene-protein:"CPP32"
;[728..733]:gene-protein:"Ich-1"
(SENT
  (S
    (NP-SBJ (PRP:[587..589] We))
    (VP (VBD:[590..597] studied)
      (NP (CD:[598..600] 52)
         (JJ:[601..613] neuroblastic) (NNS:[614..620] tumors))
      (S-PRP
        (NP-SBJ (-NONE-:[620..620] *))
        (VP (TO:[621..623] to)
          (VP (VB:[624..628] test)
            (SBAR-NOM (IN:[630..637] whether)
              (S
                (NP-SBJ-1
                  (NP (DT:[638..641] the)
                    (ADJP
                      (NML (NN:[642..646] cell) (NN:[647..652] death))
                      (HYPH:[652..653] -) (VBN:[653..660] related))
                    (NNS:[661..670] proteases))
                  (,:[670..671] ,)
                  (NP
                    (NP
                      (NML
                        (ADJP
                          (NML (NN:[672..685] interleukin-1)
                               (SYM:[686..690] beta))
                          (VBG:[691..701] converting))
                        (NN:[702..708] enzyme))
                      (NML (-LRB-:[710..711] -LRB-) (NN:[711..714] ICE)
                           (-RRB-:[714..715] -RRB-)))
                    (,:[715..716] ,)
                    (NP (NN:[717..722] CPP32))
                    (,:[722..723] ,) (CC:[724..727] and)
                    (NP (NN:[728..733] Ich-1))))
                (,:[733..734] ,)
                (VP (VBD:[735..739] were)
                  (VP (VBN:[740..748] involved)
                    (NP-1 (-NONE-:[748..748] *))
                    (PP-CLR (IN:[749..751] in)
                      (NP
                        (NP (DT:[752..755] the) (NN:[756..766] regression))
                        (PP (IN:[767..769] of)
                          (NP (DT:[770..773] the) (NNS:[774..780] tumors)))))))))))))
    (.:[780..781] .)))

;sentence 6 Span:782..967
;High  levels of expression of ICE and CPP32 were significantly correlated
;with a high  level of TRK-A expression, single copy of N-myc, younger age,
;lower stages, and  better prognosis.
;[812..815]:gene-protein:"ICE"
;[820..825]:gene-protein:"CPP32"
;[878..883]:gene-protein:"TRK-A"
;[911..916]:gene-rna:"N-myc"
;[918..929]:malignancy-developmental-state:"younger age"
;[931..943]:malignancy-clinical-stage:"lower stages"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[782..786] High) (NNS:[788..794] levels))
      (PP (IN:[795..797] of)
        (NP
          (NP (NN:[798..808] expression))
          (PP (IN:[809..811] of)
            (NP (NN:[812..815] ICE) (CC:[816..819] and) (NN:[820..825] CPP32))))))
    (VP (VBD:[826..830] were)
      (ADVP (RB:[831..844] significantly))
      (VP (VBN:[845..855] correlated)
        (NP-1 (-NONE-:[855..855] *))
        (PP-CLR (IN:[856..860] with)
          (NP
            (NP
              (NP (DT:[861..862] a) (JJ:[863..867] high) (NN:[869..874] level))
              (PP (IN:[875..877] of)
                (NP (NN:[878..883] TRK-A) (NN:[884..894] expression))))
            (,:[894..895] ,)
            (NP
              (NP (JJ:[896..902] single) (NN:[903..907] copy))
              (PP (IN:[908..910] of)
                (NP (NN:[911..916] N-myc))))
            (,:[916..917] ,)
            (NP (JJR:[918..925] younger) (NN:[926..929] age))
            (,:[929..930] ,)
            (NP (JJR:[931..936] lower) (NNS:[937..943] stages))
            (,:[943..944] ,) (CC:[945..948] and)
            (NP (JJR:[950..956] better) (NN:[957..966] prognosis))))))
    (.:[966..967] .)))

;sentence 7 Span:968..1216
;The immunohistochemical studies and Western analyses as well  as the terminal
;dUTP-biotin nick end labeling (TUNEL) method revealed that both  ICE and
;CPP32 were translocated from the cytoplasm into the nuclei in  regressing,
;apoptotic tumor cells.
;[1051..1057]:gene-protein:"biotin"
;[1111..1114]:gene-protein:"ICE"
;[1119..1124]:gene-protein:"CPP32"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[968..971] The)
        (NML
          (NML (JJ:[972..991] immunohistochemical) (NNS:[992..999] studies))
          (CC:[1000..1003] and)
          (NML (JJ:[1004..1011] Western) (NNS:[1012..1020] analyses))))
      (CONJP (RB:[1021..1023] as) (RB:[1024..1028] well) (IN:[1030..1032] as))
      (NP (DT:[1033..1036] the)
        (NML
          (NML (JJ:[1037..1045] terminal) (NN:[1046..1051] dUTP-)
               (NN:[1051..1057] biotin) (NN:[1058..1062] nick)
               (NN:[1063..1066] end) (NN:[1067..1075] labeling))
          (NML (-LRB-:[1076..1077] -LRB-) (NN:[1077..1082] TUNEL)
               (-RRB-:[1082..1083] -RRB-)))
        (NN:[1084..1090] method)))
    (VP (VBD:[1091..1099] revealed)
      (SBAR (IN:[1100..1104] that)
        (S
          (NP-SBJ-1 (CC:[1105..1109] both) (NN:[1111..1114] ICE)
                    (CC:[1115..1118] and) (NN:[1119..1124] CPP32))
          (VP (VBD:[1125..1129] were)
            (VP (VBN:[1130..1142] translocated)
              (NP-1 (-NONE-:[1142..1142] *))
              (PP-DIR (IN:[1143..1147] from)
                (NP (DT:[1148..1151] the) (NN:[1152..1161] cytoplasm)))
              (PP-DIR (IN:[1162..1166] into)
                (NP (DT:[1167..1170] the) (NNS:[1171..1177] nuclei)))
              (PP-LOC (IN:[1178..1180] in)
                (NP (VBG:[1182..1192] regressing) (,:[1192..1193] ,)
                    (JJ:[1194..1203] apoptotic) (NN:[1204..1209] tumor)
                    (NNS:[1210..1215] cells))))))))
    (.:[1215..1216] .)))

;sentence 8 Span:1217..1372
;Our results suggest that ICE and CPP32  cysteine proteases may play an
;important role in regulating the apoptotic  process of the favorable
;neuroblastomas.
;[1242..1245]:gene-protein:"ICE"
;[1250..1255]:gene-protein:"CPP32"
;[1257..1275]:gene-protein:"cysteine proteases"
;[1357..1371]:malignancy-type:"neuroblastomas"
(SENT
  (S
    (NP-SBJ (PRP$:[1217..1220] Our) (NNS:[1221..1228] results))
    (VP (VBP:[1229..1236] suggest)
      (SBAR (IN:[1237..1241] that)
        (S
          (NP-SBJ
            (NP (NN:[1242..1245] ICE)
              (NML-1 (-NONE-:[1245..1245] *P*)))
            (CC:[1246..1249] and)
            (NP (NN:[1250..1255] CPP32)
              (NML-1 (NN:[1257..1265] cysteine) (NNS:[1266..1275] proteases))))
          (VP (MD:[1276..1279] may)
            (VP (VB:[1280..1284] play)
              (NP (DT:[1285..1287] an) (JJ:[1288..1297] important)
                  (NN:[1298..1302] role))
              (PP (IN:[1303..1305] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1305..1305] *))
                  (VP (VBG:[1306..1316] regulating)
                    (NP
                      (NP (DT:[1317..1320] the) (JJ:[1321..1330] apoptotic)
                          (NN:[1332..1339] process))
                      (PP (IN:[1340..1342] of)
                        (NP (DT:[1343..1346] the) (JJ:[1347..1356] favorable)
                            (NNS:[1357..1371] neuroblastomas))))))))))))
    (.:[1371..1372] .)))

;section 9 Span:1376..1420
;PMID: 9377572 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1376..1380] PMID) (::[1380..1381] :) (CD:[1382..1389] 9377572)
        (NN:[1390..1391] -LSB-) (NNP:[1391..1397] PubMed) (::[1398..1399] -)
        (NN:[1400..1407] indexed) (IN:[1408..1411] for)
        (NNP:[1412..1420] MEDLINE-RSB-)))
